Clinical Trial Update: Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment [Phase 4]

View source ↗

Summary

A completed Phase 4 study characterizing HDL properties in people with Type 2 Diabetes and dyslipidemia after treatment with fenofibrate or niacin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• FENOFIBRATE (Fenofibrate)
• Niacin (nicotinic acid)

Snippet

Sponsor: Institut Investigacio Sanitaria Pere Virgili | Conditions: Type 2 Diabetes Mellitus, Dyslipidemia | Phase 4 | Status: COMPLETED